Page 89 - Cardiac Nursing

Pa
Pa
2-0
g
g
Pa
2-0
p
p
ta
04
04
p
g
0
0
q
xd
xd
0
5:3
5 A
e 6
e 6
6/3
6/3
5 A
3
68.
68.
3
1
1
5:3
q
LWBK340-c02_
LWB
LWB K34 0-c 02_ p p pp042-068.qxd 06/30/2009 15:33 Page 65 Aptara a a
K34
q
02_
0-c
0/2
0/2
009
ta
r
r
009
C HAPTER 2 / Systemic and Pulmonary Circulation and Oxygen Delivery 65
16. Simionescu, M., & Simionescu, N. (1984). Ultrastructure of the mi- 43. Cohen, R. (2000). Role of nitric oxide in vasomotor regulation. In J.
crovascular wall: Functional correlations. In E. Renkin & C. Michel Loscalzo & J. Vita (Eds.), Contemporary cardiology: Nitric oxide and the
(Eds.), Handbook of physiology: Microcirculation (pp. 41–101). Bethesda, cardiovascular system (pp. 105–122). Totowa, NJ: Humana Press.
MD: American Physiological Society. 44. Moncada, S., & Higgs, E. A. (2006). Nitric oxide and the vascular en-
17. Charkoudian, N. (2003). Skin blood flow in adult human thermoregu- dothelium. Handbook of Experimental Pharmacology, 213–254.
d
lation: How it works, when it does not, and why. Mayo Clinics Proceeding, 45. Vanhoutte, P. M. (2000). Say NO to ET. Journal of the Autonomic
d
78, 603–612. Nervous System, 81, 271–277.
18. Pries, A. R., & Kuebler, W. M. (2006). Normal endothelium. Handbook 46. Alonso, D., & Radomski, M. W. (2003). The nitric oxide-endothelin-1
of Experimental Pharmacology, 1, (176, Pt. 1):1–40. connection. Heart Failure Review, 8, 107–115.
19. Schneeberger, E. E., & Lynch, R. D. (2004). The tight junction: A mul- 47. Busse, R., & Fleming, I. (2006). Vascular endothelium and blood flow.
tifunctional complex. American Journal of Physiology and Cellular Physi- Handbook of Experimental Pharmacology, 43–78.
6
ology, 286, C1213–C1228. 48. Iida, N. (1999). Nitric oxide mediates sympathetic vasoconstriction at
6
20. Raju, S., Fredericks, R., Lishman, P., et al. (1993). Observations on the supraspinal, spinal, and synaptic levels. American Journal of Physiology,
calf venous pump mechanism: Determinants of postexercise pressure. 276, H918–H925.
6
6
7
Journal of Vascular Surgery, 17, 459–469. 49. McHugh, J., & Cheek, D. J. (1998). Nitric oxide and regulation of
7
l
l
21. Rowell, L. (1993). Human cardiovascular control. New York: Oxford vascular tone: Pharmacological and physiological considerations. American
7
7
University Press. Journal of Critical Care, 7, 131–140.
22. Caggiati, A., Phillips, M., Lametschwandtner, A., et al. (2006). Valves in 50. Ignarro, L. J. (2002). After 130 years, the molecular mechanism of ac-
small veins and venules. European Journal of Vascular and Endovascular tion of nitroglycerin is revealed. Proceedings of the National Academy of
Surgery, 32, 447–452. Science USA, 99, 7816–7817.
23. Rowell, L. (1986). Human circulation: Regulation during physical stress. 51. Ignarro, L. J. (2002). Nitric oxide as a unique signaling molecule in the
New York: Oxford University Press. vascular system: A historical overview. Journal of Physiology and Pharma-
24. Hainsworth, R. (1986). Vascular capacitance: Its control and impor- cology, 53, 503–514.
tance. Review of Physiology and Biochemistry, 105, 101–173. 52. Loscalzo, J. (2001). Nitric oxide insufficiency, platelet activation, and ar-
25. Rowell, L., O’Leary, D., & Kellogg, D. (1996). Integration of cardio- terial thrombosis. Circulation Research, 88, 756–762.
vascular control systems in dynamic exercise. In L. Rowell & J. Sheperd 53. Ahanchi, S. S., Tsihlis, N. D., & Kibbe, M. R. (2007). The role of ni-
(Eds.), Handbook of physiology. Exercise: Regulation and integration of tric oxide in the pathophysiology of intimal hyperplasia. Journal of Vas-
multiple systems (pp. 770–838). Bethesda, MD: Oxford University Press. cular Surgery, 45(Suppl. A), A64–A73.
26. Aukland, K. (2005). Arnold Heller and the lymph pump. Acta Physio- 54. Friedewald, V. E., Giles, T. D., Pool, J. L., et al. (2008). The Editor’s
logica Scandinavia, 185, 171–180. Roundtable: Endothelial dysfunction in cardiovascular disease. Ameri-
27. Zawieja, D. (2005). Lymphatic biology and the microcirculation: Past, can Journal of Cardiology, 102, 418–423.
present and future. Microcirculation, 12, 141–150. 55. Behrendt, D., & Ganz, P. (2002). Endothelial function. From vascular
28. Muthuchamy, M., & Zawieja, D. (2008). Molecular regulation of lym- biology to clinical applications. American Journal of Cardiology, 90,
phatic contractility. Annals of the New York Academy of Sciences, 1131, 40L–48L.
89–99. 56. Fernandes, D., & Assreuy, J. (2008). Nitric oxide and vascular reactivity
29. Schmid-Schonbein, G. (1990). Microlymphatics and lymph flow. Phys- in sepsis. Shock, 30(Suppl. 1), 10–13.
iology in Review, 70, 987–1028. 57. Galkin, A., Higgs, A., & Moncada, S. (2007). Nitric oxide and hypoxia.
30. Gashev, A. A. (2008). Lymphatic vessels: Pressure- and flow-dependent Essays in Biochemistry, 43, 29–42.
regulatory reactions. Annals of the New York Academy of Sciences, 1131, 58. Trzeciak, S., Cinel, I., Phillip Dellinger, R., et al. (2008). Resuscitating
100–109. the microcirculation in sepsis: The central role of nitric oxide, emerging
31. Olszewski, W. L. (2002). Contractility patterns of normal and patho- concepts for novel therapies, and challenges for clinical trials. Academy
logically changed human lymphatics. Annals of the New York Academy of of Emergency Medicine, 15, 399–413.
Sciences, 979, 52–63. 59. Mitchell, J. A., Ali, F., Bailey, L., et al. (2008). Role of nitric oxide and
32. Gashev, A. A. (2002). Physiologic aspects of lymphatic contractile func- prostacyclin as vasoactive hormones released by the endothelium.
tion: Current perspectives. Annals of the New York Academy of Sciences, Experimental Physiology, 93, 141–147.
979, 178–187. 60. Mollace, V., Muscoli, C., Masini, E., et al. (2005). Modulation of
33. Small, J., & Gimona, M. (1998). The cytoskeleton of the vertebrate prostaglandin biosynthesis by nitric oxide and nitric oxide donors.
7
7
4
smooth muscle cell. Acta Physiologica Scandinavia, 164, 341–348. Pharmacology in Review, 57, 217–252.
4
34. Somlyo, A., & Somlyo, A. (2002). The sarcoplasmic reticulum: Then 61. Bellien, J., Thuillez, C., & Joannides, R. (2008). Contribution of en-
and now. Novartis Foundation Symposia, 246, 258–268; discussion dothelium-derived hyperpolarizing factors to the regulation of vascu-
6
6
268–271, 272–276. lar tone in humans. Fundamentals of Clinical Pharmacology, 22,
35. Horowitz, A., Menice, C., Laporte, R., et al. (1996). Mechanisms of 363–377.
6
6
smooth muscle contraction. Physiology in Review, 76, 967–1003. 62. Lushka, L., Agewall, S., & Kublickiene, K. (2008). Endothelium-de-
36. Griendling, K. K., Harrison, D., & Alexander, R. (2008). Biology of the rived hyperpolarizing factor in vascular physiology and cardiovascular
vessel wall. In V. Fuster, R. Walsh, & M. F. O’Rourke (Eds.), Hurst’s the disease. Atherosclerosis; doi:10.1016/j.atherosclerosis.2008.06.008.
heart. New York: McGraw-Hill. 63. Feletou, M., & Vanhoutte, P. M. (2006). Endothelium-derived hyper-
37. Wiel, E., Vallet, B., ten Cate, H. (2005). The endothelium in intensive polarizing factor: Where are we now? Arteriosclerosis and Thrombosis Vas-
care. Critical Care Clinics, 21, 403–416. cular Biology, 26, 1215–1225.
6
6
38. Furchott, R., & Zawadzki, J. (1980). The obligatory role of endothelial 64. Feletou, M., & Vanhoutte, P. M. Endothelial dysfunction: A multifac-
cells in the relaxation of arterial smooth muscle by acetylcholine. Nature, eted disorder (The Wiggers Award Lecture). American Journal of Physi-
288, 373–376. ology Heart Circulation Physiology, 291, H985–H1002.
39. Ignarro, L. J., Buga, G. M., Wood, K. S., et al. (1987). Endothelium-de- 65. Feletou, M., & Vanhoutte, P. M. (2007). Endothelium-dependent hy-
rived relaxing factor produced and released from artery and vein is nitric perpolarizations: Past beliefs and present facts. Annals of Medicine, 39,
oxide. Proceedings of the National Academy of Sciences USA, 84, 495–516.
9265–9269. 66. Yang, Q., Yim, A. P., & He, G. W. (2007). The significance of endothe-
40. Palmer, R., Ferrige, A., & Moncada, S. (1987). Nitric oxide release ac- lium-derived hyperpolarizing factor in the human circulation. Current
counts for the biological activity of endothelium-derived relaxing factor. Vascular Pharmacology, 5, 85–92.
7
7
Nature, 327, 524–526. 67. Yanigisawa, M., Kurihara, H., & Kimura, S. (1988). A novel potent
41. Luscher, T. F. (1991). Endothelium-derived nitric oxide: The endoge- vasoconstrictor peptide produced by vascular endothelial cells. Nature,
nous nitrovasodilator in the human cardiovascular system. European 332, 411–415.
Heart Journal, 12(Suppl. E), 2–11. 68. Shah, R. (2007). Endothelins in health and disease. European Journal of
42. Moncada, S., Palmer, R., & Higgs, E. (1991). Nitric oxide: Physiology, Internal Medicine, 18, 272–282.
pathophysiology, and pharmacology. Pharmacology in Review, 43, 69. Stauffer, B. L., Westby, C. M., & DeSouza, C. A. (2008). Endothelin-1,
109–142. aging and hypertension. Current Opinion in Cardiology, 23, 350–355.